217 related articles for article (PubMed ID: 25458324)
1. Pre-diabetes and the risk of contrast induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Di Giovine G; Marino P; Suryapranata H; De Luca G
Diabetes Res Clin Pract; 2014 Dec; 106(3):458-64. PubMed ID: 25458324
[TBL] [Abstract][Full Text] [Related]
2. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
[TBL] [Abstract][Full Text] [Related]
3. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
Barbieri L; Verdoia M; Suryapranata H; De Luca G;
Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
[TBL] [Abstract][Full Text] [Related]
4. A simple risk score model for predicting contrast-induced nephropathy after coronary angiography in patients with diabetes.
Zeng JF; Chen SQ; Ye JF; Chen Y; Lei L; Liu XQ; Liu Y; Wang Y; Lin JJ; Chen JY
Clin Exp Nephrol; 2019 Jul; 23(7):969-981. PubMed ID: 31049747
[TBL] [Abstract][Full Text] [Related]
5. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
[TBL] [Abstract][Full Text] [Related]
6. Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention.
Zhang H; Fu H; Fu X; Zhang J; Zhang P; Yang S; Zeng Z; Fu N; Guo Z
BMC Nephrol; 2021 Jun; 22(1):206. PubMed ID: 34078303
[TBL] [Abstract][Full Text] [Related]
7. Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography.
Kanbay M; Siriopol D; Ozdogan E; Afsar B; Ertuglu LA; Grigore M; Sag AA; Kuwabara M; Lanaspa MA; Ortiz A; Johnson RJ; Covic A
Int Urol Nephrol; 2020 Mar; 52(3):541-547. PubMed ID: 32008199
[TBL] [Abstract][Full Text] [Related]
8. Preoperative Fasting Blood Glucose Levels and the Risk of Contrast-Induced Nephropathy in Patients With Diabetes and Pre-diabetes Undergoing Coronary Arteriography or Percutaneous Coronary Intervention: A Cross-Sectional Study.
Zhang P; Fu H; Liu J; Liu X; Yang S; Guo Z; Fu N
Angiology; 2022 Aug; 73(7):660-667. PubMed ID: 35084237
[TBL] [Abstract][Full Text] [Related]
9. Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.
Capodanno D; Ministeri M; Cumbo S; Dalessandro V; Tamburino C
Catheter Cardiovasc Interv; 2014 May; 83(6):907-12. PubMed ID: 23934631
[TBL] [Abstract][Full Text] [Related]
10. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
[TBL] [Abstract][Full Text] [Related]
11. Increased urinary adiponectin level is associated with contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention.
Zhang JY; Wang Q; Wang RT; Li F; Cheng HX; Lian K; Liu Y; Tao L
BMC Cardiovasc Disord; 2019 Jul; 19(1):160. PubMed ID: 31269899
[TBL] [Abstract][Full Text] [Related]
12. CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience.
Wang Y; Zhao HW; Zhang XJ; Chen BJ; Yu GN; Hou AJ; Luan B
BMC Cardiovasc Disord; 2019 Mar; 19(1):74. PubMed ID: 30922230
[TBL] [Abstract][Full Text] [Related]
13. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
14. CHADS2 score predicts risk of contrast-induced nephropathy in stable coronary artery disease patients undergoing percutaneous coronary interventions.
Chou RH; Huang PH; Hsu CY; Leu HB; Huang SS; Huang CC; Chen JW; Lin SJ
J Formos Med Assoc; 2016 Jul; 115(7):501-9. PubMed ID: 26830105
[TBL] [Abstract][Full Text] [Related]
15. Impact of Transient or Persistent Contrast-induced Nephropathy on Long-term Mortality After Elective Percutaneous Coronary Intervention.
Abe M; Morimoto T; Nakagawa Y; Furukawa Y; Ono K; Kato T; Kadota K; Ando K; Ishii M; Masunaga N; Akao M; Kimura T
Am J Cardiol; 2017 Dec; 120(12):2146-2153. PubMed ID: 29106836
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Contrast-Induced Nephropathy in Patients Without Baseline Renal Dysfunction Undergoing Coronary Angiography.
Chen SQ; Liu Y; Smyth B; Li HL; Sun GL; Chen ZJ; Zhou YL
Heart Lung Circ; 2019 Jun; 28(6):866-873. PubMed ID: 29960836
[TBL] [Abstract][Full Text] [Related]
17. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
18. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention.
Barbieri L; Verdoia M; Marino P; Suryapranata H; De Luca G;
Eur J Prev Cardiol; 2016 Jun; 23(9):931-7. PubMed ID: 26525064
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of post-procedural hyponatremia on contrast-induced nephropathy in patients who underwent coronary angiography or percutaneous coronary intervention.
Gucun M; Kahyaoglu M; Celik M; Guner A; Akyuz O; Yilmaz Y
Acta Cardiol; 2022 May; 77(3):215-221. PubMed ID: 34032177
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
